Table 15 Top 10 pairs of drugs with their correlation with subtype 3 of breast cancer, considering both combined and individually
From: Computationally repurposing drugs for breast cancer subtypes using a network-based approach
Drug1 | Drug2 | C. Cor. | Cor. 1 | Cor. 2 | C. Rank | Rank 1 | Rank 2 |
|---|---|---|---|---|---|---|---|
Tadalafil | Acyclovir | − 0.79 | − 0.61 | − 0.45 | 1 | 4 | 73 |
Tadalafil | Fomepizole | − 0.78 | − 0.61 | − 0.43 | 2 | 4 | 100 |
Rupatadine | ICI-185282 | − 0.77 | − 0.58 | − 0.52 | 3 | 6 | 21 |
Deferiprone | Etofylline-Clofibrate | − 0.76 | − 0.62 | − 0.57 | 4 | 3 | 9 |
Deferiprone | Rupatadine | − 0.75 | − 0.62 | − 0.58 | 5 | 3 | 6 |
Ruxolitinib | Ribavirin | − 0.74 | − 0.68 | − 0.57 | 6 | 2 | 7 |
L-690330 | Favipiravir | − 0.74 | − 0.49 | − 0.47 | 7 | 38 | 54 |
Raclopride | Hymecromone | − 0.74 | − 0.54 | − 0.48 | 8 | 13 | 48 |
EDTA | Pregnenolone | − 0.74 | − 0.56 | − 0.51 | 9 | 10 | 28 |
Raclopride | Artesunate | − 0.74 | − 0.54 | − 0.47 | 10 | 13 | 59 |